Humacyte Inc (HUMA)
6.33
-0.09
(-1.40%)
USD |
NASDAQ |
May 17, 16:00
6.35
+0.02
(+0.32%)
After-Hours: 16:09
Humacyte Free Cash Flow (Quarterly): -27.74M for March 31, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -27.74M |
| December 31, 2023 | -19.20M |
| September 30, 2023 | -13.50M |
| June 30, 2023 | -23.09M |
| March 31, 2023 | -19.79M |
| December 31, 2022 | -19.64M |
| September 30, 2022 | -17.02M |
| Date | Value |
|---|---|
| June 30, 2022 | -16.70M |
| March 31, 2022 | -18.82M |
| December 31, 2021 | -21.49M |
| September 30, 2021 | -30.60M |
| June 30, 2021 | -14.74M |
| March 31, 2021 | -14.57M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-30.60M
Minimum
Sep 2021
-13.50M
Maximum
Sep 2023
-19.76M
Average
-19.20M
Median
Dec 2023
Free Cash Flow (Quarterly) Benchmarks
| Adial Pharmaceuticals Inc | -1.223M |
| Gritstone Bio Inc | -33.71M |
| Precision BioSciences Inc | -19.07M |
| Puma Biotechnology Inc | 11.25M |
| Revance Therapeutics Inc | -71.11M |